{
  "id": 20884015,
  "title": "Trulieve Was the First U.S. Pure-Play Cannabis Stock on the NYSE. Here's Which Stock Could Be Next.",
  "url": "https://urgent.news/2026/11/20/trulieve-was-the-first-u-s-pure-play-cannabis-stock-on-the-nyse-heres",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T09:50:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/20/trulieve-was-the-first-us-pure-play-cannabis-stock-on-the-nyse-heres-which-stock-could-be-next/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Trulieve Cannabis made history as the first U.S. pure-play cannabis company to list on the New York Stock Exchange (NYSE) on June 10, marking a significant milestone for the industry. This achievement came after a major shift in federal marijuana policy, where the April 2026 decision moved state-licensed medical marijuana into Schedule III, opening doors for therapeutic drugs to trade on major exchanges. Trulieve's success prompted speculation about which other cannabis companies might follow suit.\n\nGreen Thumb Industries (GTBIF), one of the largest cannabis operators in the country, is a potential candidate for a major NYSE listing. The company boasts impressive financial metrics, including $324.4 million in revenue, an 11% year-over-year increase, and normalized EBITDA of $89.4 million, representing a 27.6% margin. Moreover, Green Thumb generated $58.3 million in operating cash flow and holds $316 million in cash reserves, demonstrating financial stability.\n\nHowever, Green Thumb faces regulatory challenges and hasn't announced an uplisting plan. Unlike Trulieve, which operates solely in the medical cannabis market post-structure, Green Thumb continues to serve both recreational and medical customers, complicating its path to a regulated listing. Despite these hurdles, the company has been returning capital to shareholders through a stock repurchase program, buying back about 29.5 million shares at a cost of $203.4 million since 2023.\n\nIf federal cannabis reforms continue and major exchanges become more accessible to U.S. operators, Green Thumb's robust financials position it as a credible contender to follow Trulieve into the NYSE. While an official listing date remains undetermined, Green Thumb's profile, financial strength, and strategic position make it a compelling candidate for the next cannabis stock to be listed on Wall Street.",
  "summary": "Another cannabis company has rising revenue, strengthening its case for an exchange listing.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Trulieve Was the First U.S. Pure-Play Cannabis Stock on the NYSE. Here's Which Stock Could Be Next.",
        "url": "https://urgent.news/2026/11/20/trulieve-was-the-first-u-s-pure-play-cannabis-stock-on-the-nyse-heres-20885957",
        "published": "2026-11-20T10:10:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}